• enGene Therapeutics reported updated interim results from Phase 2 LEGEND pivotal cohort testing detalimogene in high-risk, BCG-unresponsive non-muscle invasive bladder cancer, with data cut as of April 21, 2026.
• Responses were seen in more than half of treated patients at some point, with fewer patients remaining cancer-free at later follow-ups, raising durability questions.
• Disease worsening to more advanced stages remained uncommon, supporting continued use of bladder-sparing approaches for many patients.
• Safety profile stayed broadly manageable, with most treatment-related side effects mild and few patients stopping therapy due to adverse events.
• Results will be presented at plenary session during American Urological Association meeting on May 15, 2026, with FDA discussions continuing ahead of potential BLA filing and update expected in second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Therapeutics Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260507845702) on May 07, 2026, and is solely responsible for the information contained therein.